Gastric Cancer Treatment Shows Survival Benefit in Phase III Trial

The CLARITY-Gastric01 Phase III trial demonstrated that sonesitatug vedotin significantly improved overall survival for patients with advanced Claudin 18.2-positive gastric or gastroesophageal junction cancers. This antibody-drug conjugate could become a new precision treatment option, offering hope for a broad patient population with this aggressive disease.